GlassScriptPhysician profile
Lisa K Medlin
NPI 1073587283
$1,552.67
in general payments reported to CMS, 2019-2025
18 companies · $529 in 2025
The $529 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $21.55 · 2023: $40.40 · 2024: $962 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,531.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $366.55 | 2023-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $273.16 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $192.81 | 2024-2025 | Caplyta |
| Abbvie INC. | $171.38 | 2024-2025 | |
| Ardelyx, INC. | $141.64 | 2024 | Ibsrela |
| Vanda Pharmaceuticals INC. | $54.44 | 2024 | Hetlioz, Fanapt |
| Exact Sciences Corporation | $49.74 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.26 | 2024 | |
| Glaxosmithkline, LLC. | $44.20 | 2025 | Trelegy Ellipta |
| Idorsia Pharmaceuticals US INC | $42.65 | 2024 | Quviviq |
| Novo Nordisk INC | $32.85 | 2025 | Wegovy |
| Pfizer INC. | $22.25 | 2024 | |
| Edwards Lifesciences Corporation | $21.55 | 2022 | |
| Acella Pharmaceuticals, LLC | $20.53 | 2024 | NP Thyroid 60 |
| Lundbeck LLC | $19.66 | 2024 | Rexulti |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $18.19 | 2023 | Adthyza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.11 | 2024 | Trulance, Xifaxan |
| Janssen Pharmaceuticals, INC | $14.70 | 2024 | Spravato |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Medlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.